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ABSTRACT
Estrogen hormones are implicated in a majority of
breast cancers and estrogen receptor alpha (ER),
the main nuclear factor mediating estrogen signal-
ing, orchestrates a complex molecular circuitry that
is not yet fully elucidated. Here, we investigated
genome-wide DNA methylation, histone acetylation
and transcription after estradiol (E2) deprivation and
re-stimulation to better characterize the ability of ER
to coordinate gene regulation. We found that E2 de-
privation mostly resulted in DNA hypermethylation
and histone deacetylation in enhancers. Transcrip-
tome analysis revealed that E2 deprivation leads to
a global down-regulation in gene expression, and
more specifically of TET2 demethylase that may
be involved in the DNA hypermethylation following
short-term E2 deprivation. Further enrichment anal-
ysis of transcription factor (TF) binding and motif
occurrence highlights the importance of ER connec-
tion mainly with two partner TF families, AP-1 and
FOX. These interactions take place in the proximity
of E2 deprivation-mediated differentially methylated
and histone acetylated enhancers. Finally, while most
deprivation-dependent epigenetic changes were re-
versed following E2 re-stimulation, DNA hypermethy-
lation and H3K27 deacetylation at certain enhancers
were partially retained. Overall, these results show
that inactivation of ER mediates rapid and mostly re-
versible epigenetic changes at enhancers, and bring
new insight into early events, which may ultimately
lead to endocrine resistance.
INTRODUCTION
Despite the continuous efforts for prevention and surveil-
lance, breast cancer (BC) remains the most common can-
cer in women across the world (1). Among established risk
factors, steroid hormones, notably estrogens, have been rec-
ognized as key players in BC, and current chemopreven-
tive strategies target hormonally responsive breast tumours.
BCs are classified into different molecular subtypes mainly
according to the presence of estrogen receptor (ER), pro-
gesterone receptor (PR) and epidermal growth factor re-
ceptor 2 (HER2), and their expression tends to determine
the treatment approach. While on average only 7% of nor-
mal mammary epithelial cells express ER, more than 70% of
breast tumours are ER-positive (ER+) which suggests that
ER+ cells are more prone to oncogenesis, presumably due
to their ability to respond to a variety of biological (endoge-
nous estrogens) and environmental stimuli (such as steroid-
like molecules) (2,3). In addition, treatment of ER+ BC pa-
tients is based on this characteristic as it lends itself readily
to anti-estrogen therapy that down-regulates ER signalling
and hence inhibits ER-induced cell proliferation. Unfortu-
nately, patients regularly develop a non-reversible resistance
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to anti-estrogen therapy, underscoring the importance of
understanding ER pathway regulation in hormone-driven
breast cancer (4).
The central role of ER in BC development, progression
and treatment has prompted the development of mecha-
nistic models of the activity of this nuclear factor to study
the regulation of transcription, chromatin structure and epi-
genetic marks. The nuclear receptor super-family to which
ER belongs, has the dual characteristic of acting both as
a TF binding to DNA and as a ligand receptor binding
to a variety of steroid-like molecules, including estrogens,
androgens or progestogens (5). To decipher the molecu-
lar mechanisms that ER triggers upon ligand activation,
estrogen-responding breast cancer cell lines, often MCF-
7 that is widely used by ENCODE (6), are deprived of
steroid stimuli for several days and re-stimulated with ago-
nist E2, after which various readouts can be measured. Fol-
lowing ligand binding, ER can either up-regulate or down-
regulate gene expression, which is achieved by recruiting dif-
ferent protein complexes (7). For instance, ER’s interaction
with epigenetic regulatory factors (ERFs) TET2, p300 or
MLL3 and with TFs such as FOXA1 or GATA3, is asso-
ciated with positive gene regulation while inversely, recruit-
ment of polycomb repressive complex 2 (PRC2) and DN-
MTs results in transcriptional repression (8–12). Further-
more, interactions with a variety of cofactors allow ER to
establish chromatin interactions both in cis and in trans,
mediating concerted gene expression by bringing promot-
ers and enhancers in close proximity in three-dimensional
space (13,14). Recent studies performed in cell culture mod-
els and patient samples have shown that changes in high-
order assemblies of transcription factors, including GATA3
and AP-1, can reorganize the landscape of ER-bound
enhancers, resulting in gene program transitions that pro-
mote cancer cell plasticity and development of therapy re-
sistance (15). Enhancers are usually predicted by the pres-
ence of H3K4me1, TF footprints, and p300 binding, while
enhancer activity is determined through H3K27 acetylation
and enhancer RNA (eRNA) transcription (16,17).
In an effort to better characterize enhancers, several stud-
ies have placed their attention on the DNA methylation
(DNAm) profiles of these regulatory elements and they
showed that the low and intermediate DNAm levels mea-
sured at these locations are most likely the result of dynamic
ERF and TF binding (18–20). It is now well admitted that
the majority of ER binding occurs on enhancers and it was
recently shown that ER binding on enhancers requires the
presence of the methylcytosine dioxygenase TET2 (8,12).
The integration of tumour and cell line data showed that
higher ER expression and binding correlates with lower lev-
els of DNAm in a specific panel of enhancers (21–23). How-
ever, little is known about the dynamics of ER-dependent
epigenetic changes and how variations in DNA methylation
are connected with chromatin reconfiguration and changes
in genes expression.
In the present study we sought (i) to identify epigenetic
changes that are directly attributed to ligand-mediated ER
down-regulation, (ii) to investigate the functional impact
of these changes, notably in relation to gene transcription,
chromatin activity and cooperation with other TFs and (iii)
to test whether these changes can be precluded or reversed
upon subsequent ER re-activation. By optimizing the E2
deprivation and re-stimulation cell culture protocol that
mimic the decrease of E2 levels in blood of breast cancer
patients treated with aromatase inhibitors, a treatment that
often evolves into an endocrine resistance after prolonged
use (24), in conjunction with the latest methylation arrays,
transcriptome (RNA-Seq) and chromatin (ChIP-Seq) anal-
yses, we provide new insights into the genome-wide epi-
genetic dynamics of ligand-mediated ER activity in breast
cancer cells. Our results revealed that DNA hypermethyla-
tion and histone deacetylation of enhancers is an early re-
sponse to down-regulation of ER signalling. In addition,
TF enrichment analysis revealed the AP-1 transcription fac-
tor among the top potent candidate cofactor in mediating
ER-specific DNAm maintenance at enhancers. Finally, we
observed a partial reversibility of DNAm and histone acety-
lation changes induced by sequential estrogen deprivation
and re-stimulation.
MATERIALS AND METHODS
Cell culture and treatments
MCF-7 HTB-22® cells were obtained from the Ameri-
can Type Culture Collection. Prior to E2 deprivation/re-
stimulation experiments, MCF-7 were conditioned for two
weeks to phenol-red-free DMEM/F-12 supplemented with
10% (v/v) charcoal-stripped fetal bovine serum (csFBS,
Sigma-Aldrich), 1% nonessential amino acids, sodium
pyruvate and penicillin/streptomycin (Life Technologies)
and to a daily addition of 10 nM E2 in 0.1% DMSO (Sigma-
Aldrich) at 37◦C, in a humidified and 5% CO2-enriched
atmosphere. For all assays, control cells (CTR) were cul-
tured continuously for 14 days in the above-mentioned con-
ditions, while E2-deprived cells (E2D) were cultured in the
same conditions only lacking E2. The re-stimulated cells
(ReSt) were E2-deprived for 4 days and re-stimulated with
E2 for the 10 following days. Two hours before being har-
vested, CTR and ReSt cultures were incubated with 10 nM
E2 in 0.1% DMSO while E2D were incubated only in 0.1%
DMSO. MCF-7 cells that were used as standard controls
(STD) as well as in the inhibition and siRNA assays were
maintained in the same composition of medium as men-
tioned above, but with 10% of standard FBS (Eurobio).
ICI 182 780 inhibition
For the inhibition assay, MCF-7 cells were continuously cul-
tured in presence of 1 M of ER antagonist ICI 182 780
(ICI) and CTR cells were cultured in 10% FBS medium con-
taining 0.1% DMSO. To study the persistence/reversibility
of the effect, cells were cultured with ICI for 4 days then
placed in the same medium as used for the control for 10
days to re-activate ER activity (ReAc). For both depriva-
tion and inhibition assays, cells were cultured and collected
in triplicates at day 0, 4 and 14 (Figures 1A, 5A and Sup-
plementary Figure S1E). The effectiveness of ICI treatment
was checked by measuring the expression levels of ER-
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Figure 1. E2 deprivation leads to time-increasing hypermethylation of CpGs in enhancers. (A) MCF-7 cultured in control conditions (CTR, charcoal-
stripped serum + 10nm of E2) were deprived from E2 for 4 and 14 days (E2D). All experiments were performed in triplicates. (B) ER protein levels in
MCF-7 cells grown in standard medium till passage 160 (Std; phenol-red and complete FBS), in CTR and E2D. GAPDH was used as an internal control.
(C) ER binding levels in GREB1 enhancer (left) and in SPATA16 promoter (right) for the same conditions as in (B) at d14 alone, (n = 3). Asterisks indicate
significant differences from the IgG (Student’s t-test, P < 0.05). n.s., not significant (Student’s t-test, P > 0.05). (D) Heatmap of DMPs between CTR and
E2D MCF-7 cells with at least 10% differential methylation (). (E) Overlap of 450k CpG sites between E2D DMPs, estrogen-associated emQTLs in
breast tumours (Cluster 2, Fleischer et al., 2017) and long-term E2 deprivation DMPs in MCF7 (MCF7X, Stone et al., 2015, re-analysed with limma,
FDR < 0.01;  ≥ 10%). (F) Genomic features distribution and (G) CpG density of hypermethylated DMPs (hyperDMPs, n = 950), all 850k CpG probes
(n = 866 836) and hypomethylated DMPs (hypoDMPs, n = 45). (H) Fold-enrichment of DMPs overlapping with publicly available histone ChIP-seq
data and (I) ChromHMM annotations originated from MCF-7 cells (Hnisz, 2013). Asterisks (*) mark significant enrichments (P < 10e–5, Fisher test).
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siRNA
MCF-7 at 30% confluence were transfected separetaly with
10 nM of ESR1, TET2 or non-targeting siRNA and 1 nM
of FOS siRNAs (Dharmacon, On-Target Plus siRNA) us-
ing 2.5 l of RNAiMAX lipofectamine for a 6-well format
(Life Technologies) as recommended by the manufacturer.
Cells were maintained in the lipofection for 48 h and then re-
placed by fresh medium. Cells were harvested 120h from the
day of transfection. RNA and DNA were extracted as men-
tioned in DNA methylation analysis. Expression of ESR1
and GREB1 transcripts and proteins was measured to ver-
ify the efficiency of silencing (Supplementary Figure S1B
and C). The percentage of knock-down efficiency was cal-
culated as the average of (100 – (2∧–CtsiRNA – 2–CtsiNT))
× 100.
DNA methylation analysis
For all assays, total DNA was extracted using AllPrep
DNA/RNA Mini kit (Qiagen) and was quantified by Qubit
dsDNA HS kit (Invitrogen). For the genome-wide methy-
lation analysis of CTR, E2D and ReSt samples, DNA
was bisulfite converted using the EZ DNA Methylation kit
(Zymo Research) and 250 ng were hybridized on an In-
finium MethylationEPIC array, referred to as 850k from
this point (Illumina). Processing and normalization of data
followed by identification of differentially methylated po-
sitions (DMPs) was performed as described earlier (25)
with a detection P-value ≥0.01. To determine the effect
of E2D deprivation on DNAm, we used a linear regres-
sion model where we compared E2D (n = 6) treatment
to CTR (n = 9) while adjusting for timepoint and apply-
ing a differential methylation cutoff of 10% (false discov-
ery rate, FDR < 0.05;  > 10%). Two variables were
taken into account for the linear regression used to define
the DMPs: treatment (CTR versus E2D) and time. To ex-
clude the possibility that DMPs are obtained by chance,
we shuffled the treatment annotations 10 times and we ran
the linear regression again. Not a single DMP came up
when treatment groups were mixed. Then, to test the re-
versibility of the impact of E2 deprivation, we applied a
linear regression model between CTR and ReSt samples
at d14. Minfi, limma, FDb.InfiniumMethylation.hg19 and
ChIPseeker R/Bioconductor packages were used for ob-
taining annotating the DMPs (26,27). Analysis of DNAm
in validation and in inhibition assays at a single CpG level
was done by pyrosequencing, as previously described (28).
The effect of treatment for each timepoint was tested with
pairwise comparisons using a Mann-Whitney test. Primer
sequences used for pyrosequencing may be found in Sup-
plementary Table S1.
Oxidative bisulfite treatment and hydroxymethylated DNA
immunoprecipitation
Oxidative bisulfite treatment (oxBS) of 1 g of DNA was
performed with TrueMethyl oxBS Module (Nugen), as de-
scribed in (29). Levels of 5-hydroxymethylcytosine (5hmC)
were measured by pyrosequencing and they were calcu-
lated by subtracting the proportion of Cs obtained in oxBS
from BS (5hmC% = 5mC%BS – 5mC%oxBS). For hydrox-
ymethylated DNA immunoprecipitation (hMeDIP) total
DNA was extracted using the Gentra Puregene kit (Qi-
agen), 1.25 g of which were sonicated for 6 cycles [15
s ON/90 s OFF] on a Bioruptor Pico. 5hmC was immuno-
precipitated using 2.5 g of anti-5hmC antibody as per the
manufacturer’s instructions (Auto hMeDIP Kit, Diagen-
ode). The enrichment was measured using qPCR that was
performed as previously described in (28) following these
conditions: denaturation 95◦C 5min, amplification [95◦C 15
s, 60◦C 60 s, 72◦C 60 s] × 40 cycles, melting curve 95◦C 60 s,
55–90◦C with 0.5◦C increment every 5 s. The percentage of
precipitated 5hmC over input was calculated as such as the
result of 2∧[(Ct(10%input) – 3.32) – Ct(hmetDNA-IP)] × 100%.
Chromatin immunoprecipitation
MCF-7 cells were cultured in CTR, E2D and ReSt condi-
tions as mentioned above and were fixed with 1% formalde-
hyde at d14 for 8 and 10 minutes for histone marks and
TFs respectively. One million cells were sonicated and pro-
cessed with the iDeal ChIP-seq kit for histones and 4 mil-
lion cells were used to immunoprecipitate TFs using the
iDeal ChIP-qPCR kit as per the manufacturer’s protocol
(Diagenode). Chromatin was sonicated over 14 cycles of [30
s ON/30 s OFF] on a Bioruptor Pico and was immunopre-
cipitated with 2.5 g of anti-H3K27ac, anti-H3K4me1 and
anti-H3K27me3 antibodies (respectively, ab4729, ab8895,
ab6002, Abcam) in duplicates and with 2.5 g of anti-
ERalpha antibody (C15100066 Diagenode) in triplicates.
H3K27ac ChIP and input libraries were prepared using the
TruSeq ChIP Sample Prep kit and we performed paired-
end sequencing with the NextSeq 500/550 High Output Kit
v2.5 (150 Cycles) (Illumina). Fastq files were trimmed using
TrimGalore for adapters and a minimum quality of Q > 30
(Babraham Bioinformatics), then mapped on hg19 using
BWA and further processed as previously described (9,30).
Mapped read numbers ranged between 125 and 165 mil-
lion. Peaks were then called with MACS2 (2.1.1.20160309)
against input and were filtered ad hoc for <1.5 kb width,
q < 0.01 and fold-change from input >5 (31). For down-
stream analysis we worked with irreproducible-discovery-
rate (IDR) thresholded peaks. Differentially bound (DB) re-
gions were identified with DiffBind between different groups
at d14 and only DB peaks with |log2FC| >1 were consid-
ered (32). ChIP-qPCR was performed in the same condi-
tions as for hMeDIP (see previous section). To test ER
binding, a GREB1 enhancer (chr2:11638671–11638726)
was used as a positive control. The promoter of SPATA16
(chr3:172859020–172859121), a gene expressed only in
testis, was used as negative control. The percentage of input
was calculated as such as the result of 2∧[(Ct(1% input) – 6.64)
– Ct(IP sample)] × 100. Primer sequences used for validation
are listed in Supplementary Table S2.
Western blot
Western blots were performed by loading 25–30 g of to-
tal MCF-7 proteins on 4–15% precast polyacrylamide gels
(Bio-Rad). The blots were incubated overnight at +4◦C with
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(1:2000, C15100066 Diagenode), anti-FOS and anti-TET2
(1:750, ab222699 and 1:1000 ab94580 Abcam) and anti-
GAPDH (1:2000, SC-32233 Santa-Cruz) for loading con-
trol. These were followed by incubation with species-
matched secondary antibodies. The detection of the anti-
body hybridization was done with the Clarity Western ECL
mix (Bio-Rad).
Gene expression analysis
Total RNA was extracted along with DNA samples using
the AllPrep DNA/RNA Mini kit (Qiagen). One g of RNA
was used for TruSeq RNA library preparation (Illumina)
following the manufacturer’s protocol and single-end se-
quencing was performed on HiSeq 2500 yielding at least
20M 50 bp-reads for each sample. Following quality con-
trol, reads were trimmed at 30 bp and mapped on hg19 with
hisat2 with mapping efficiencies of ≥87% (33). Read counts
were generated from bam files using htseq-count function
and genes with ≤10 counts-per-million in at least two sam-
ples were eliminated (34). Differentially expressed genes
(DEGs) were identified between CTR and E2D adjusting
for time and between CTR and ReSt at d14 using edgeR
(FDR < 0.05, |log2FC| > 1) (35). Targeted expression analy-
sis of specific genes was performed by quantitative RT-PCR
as previously described (28). Briefly 500 ng of RNA were
retro-transcribed using MMLV-RT and oligo(dT) primers
(Invitrogen). Target regions were amplified from 2.5 ng of
cDNA using SYBR Green (Biorad) and relative expression
was determined using RPLP0 as a housekeeping gene. The
PCR conditions used were as follows: denaturation 95◦C
5min, amplification [95◦C 15 s, 61◦C 30 s] × 40 cycles, melt-
ing curve 95◦C 60 s, 55–90◦C with 0.5◦C increment every 5
s. The expression was measured in technical and biological
triplicates and the signal was normalized over the house-
keeping gene RPLP0. The global effect of treatment was
tested with pairwise comparisons using a Mann–Whitney
test (R v3.5.1). Primer sequences are listed in Supplemen-
tary Table S3.
De novo DNA motif analysis, TF and histone enrichment and
statistics
The ChEA database, provided online by the EnrichR col-
lection of tools, was used for a first evaluation of the en-
richment of TF binding on DEGs and genes mapping close
to DMPs and DB H3K27ac regions (36). Only TF enrich-
ments with an adjusted P-value <0.05 were considered. A
de novo TF motif enrichment analysis was performed after
enlarging the genomic window to 250 bp around DMPs and
to 1 kb for DB H3K27ac, using the findMotifsGenome.pl
function from HOMER v.4.8.3 (37). Whole genomic ranges
were kept as such for de novo motif search in publicly avail-
able TF ChIP peaks. For overlaps with specific TFs, histone
marks and ChromHMM annotations, we downloaded pub-
lished histone and TF ChIP-seq peaks (Supplementary Ta-
ble S4) and we overlapped them with the genomic ranges
of DMPs, DB H3K27ac peaks and DEGs produced in
this study. All public datasets used were based on MCF-7
cells cultured in E2 containing media. E2-dependent peaks
were derived from ER peaks that were present in E2-treated
MCF-7 and absent from E2 deprived cells (38). The enrich-
ment was calculated as the ratio of genomic-range over-
lap of the differential hits over the overlap with the total
CpG probes, H3K27ac peaks or expressed genes respec-
tively for each dataset (differential/expected). More pre-
cisely, for DNAm we used the genomic ranges of all probes
on the 850k array, for H3K27ac marks we used the IDR-
thresholded peaks of CTR at d14 and for transcription we
used the genomic range of expressed genes. Fisher’s exact
test (P < 10–5) was used to evaluate the significance of en-
richments.
Pathway enrichment analysis
A gene set enrichment analysis was performed on differ-
entially expressed genes revealed by RNA-seq using col-
lection H from MSigDb (v7.1) (39). For non-coding re-
gions (DMPs and H3K27ac peak) GREAT annotations
was used.
Visualization
For the visualization of H3K27ac peaks on IGV (2.4.19),
bam files were normalized using the reads per genome cov-
erage (RPGC) normalization method. BigWig or bedgraph
format was used to visualize publicly available datasets.
Graphpad 6.0 was used for bar and scatter plots, R 3.5.1
was used for volcano and box plots, NMF package (0.21.0)
was used for heatmaps and Inkscape 0.92 was used to as-
semble layouts.
RESULTS
E2 deprivation leads to time-dependent hypermethylation of
CpGs in enhancers
To investigate the effect of inactivation of a steroid nu-
clear receptor on DNAm patterns across time, the ER-
positive cell line MCF-7 was first deprived of E2, stricto
sensu, as outlined in Figure 1A. In previous studies on ER
activity and endocrine resistance, ER-positive cells were
usually cultured in medium containing charcoal-stripped
serum (csFBS), a serum that has been stripped of the large
majority of its lipophilic substrates, including E2, andro-
gens, growth factors and cytokines (22,40) and compared to
control counterparts cultured in medium containing stan-
dard serum. Therefore, in those studies the effect of E2
was confounded with a panel of other molecules. To ad-
dress this limitation, we generated cell culture conditions
where control (CTR) and E2-deprived (E2D) ER-positive
MCF-7 cells were conditioned to the same background:
phenol-red free medium with csFBS. While E2D cells were
deprived for up to 14 days, CTR cells were supplemented
daily with E2 which allows to analyse the effects strictly re-
lated to E2 deprivation (Figure 1A). We evaluated ER levels
in our different culture conditions and observed that ER
protein levels in CTRs were comparable to culture condi-
tions with standard FBS (STD) (Figure 1B), demonstrat-
ing the equivalence of our model to previous studies focus-
ing on E2-modulated ER. Moreover, even though the tran-
scription levels of ESR1 mRNA fluctuated slightly (Supple-
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levels at 4 and 14 days of E2 deprivation (Figure 1B), con-
firming that our deprivation conditions modulate ER and
possibly its downstream targets. In line with that, we ob-
served a decrease of ER binding on a known binding site
within GREB1 enhancer, a well-described ER target (Fig-
ure 1C) (41). In deprived conditions, GREB1 also showed
a decrease in expression in a similar manner to when ESR1
expression was reduced by siRNA knockdown or after in-
hibition of the ER pathway by the common ER antagonist
drug ICI (Supplementary Figure S1B–F). Taken together,
these results indicate that our protocol modulates ER sig-
nalling according to the known ER pathway and is valid
for analysing the impact of such modulation on cells.
Following the validation of the impact of the deprivation
protocol on ER pathway, we aimed to assess the changes
in DNA methylation induced by this modulation. To this
end, DNA extracted from the three times points (day 0,
4 and 14; d0, d4 and d14 respectively) were processed on
an 850k array that measures DNAm levels across more
than 850,000 CpGs (that includes over 300 000 CpGs lo-
cated in enhancer regions). Due to a potential effect of the
time in culture on DNAm, the log-transformed methylation
values were fitted in a linear regression model contrasting
for treatment and adjusting for time (Supplementary Fig-
ure S2). Therefore, considering together two timepoints (d4
and d14) of E2-deprivation, we identified 995 DMPs (
> 10%, FDR < 0.05) between CTR and E2D samples (Fig-
ure 1D). Among those prominent DMPs, 95% were hyper-
methylated (n = 950, hyperDMPs) while the remaining were
hypomethylated (n = 45, hypoDMPs), and the magnitude
of these changes increased in time (Figure 1D, [CTR-d4
versus E2D-d4] < [CTR-d14 versus E2D-d14]). In ad-
dition, we observed a difference in DNAm levels between
CTR groups at d4 and d14 and the initial group at d0 that
could be due to cell culture. However, DNA methylation
variations are probably not due to changes in cell cycle and
accumulation of cells in a particular phase of the mitosis as
we did not observe a change in cell proliferation following
E2 deprivation. The gain of methylation was further vali-
dated at a subset of top E2-dependent DMPs by pyrose-
quencing in two independent E2 deprivation experiments
as well as by siRNA knock-down of ESR1 (Supplementary
Figure S3A and B). These results show that E2 deprivation
leads to a significant increase of DNAm as early as 4 days
after the beginning of deprivation and this wide ranging hy-
permethylation becomes more pronounced with time.
Among the 995 identified DMPs, about a third (n = 281)
can also be found on the former version of the Illumina
array that covers over 450,000 CpG sites (450k). There-
fore, to further validate and identify specific differences in
DNAm in response to E2 deprivation, we overlapped the
450k DMPs that were obtained following our short-term
(d4 and d14) E2-deprivation with two published sets of 450k
DMPs: the first set of CpG sites from estrogen-associated
emQTLs that are differentially methylated between ER-
positive and ER-negative breast tumours (Cluster 2, (21))
and a second set of DMPs obtained by a long-term E2
deprivation of MCF7 (MCF7X, (22)). Interestingly 145
DMPs were common between cells deprived from E2 for
a short (E2D) and long period suggesting that those events
represent an early response of cells to E2 deprivation. Five
CpGs were common among all the three datasets, four of
which (cg03998598, cg13860360, cg02671171, cg20288000)
were hypermethylated in ER-negative tumours as well as in
short and long-term E2 deprived MCF-7 cells (Figure 1E).
In particular, cg20288000 site is found in an enhancer of
CASZ1, a gene coding for a TF that is involved in different
cancers, including epithelial ovarian cancer (42) consistent
with the notion that hypermethylation of enhancers may be
observed after reduced ER activity in tumours.
Analysis of genomic features exhibiting differential
methylation in response to E2 deprivation showed that
hypermethylated DMPs (hyperDMPs) were markedly en-
riched in intronic and CpG-poor contexts (Figure 1F and
G). In contrast, hypoDMPs, represented by a low number
of DMPs, were not significantly enriched in any particular
feature. In order to further investigate the potential function
of these DNAm changes, we overlapped DMPs with pub-
licly available ChIP-Seq datasets for histone modifications
that are commonly used to define chromatin state and that
were available in MCF-7 cultured in standard medium con-
taining E2 among other hormones (Supplementary Table
S4). Our analysis revealed that hyperDMPs were positively
enriched in both H3K4me1 and H3K27ac marks (79.0%
and 27.9% of hyperDMPs, respectively), which suggests
that hypermethylation occurs in putative active enhancer
regions (Figure 1H). In contrast, we observed that hyper-
DMPs were depleted (14.2%) in H3K4me3 marks (known
to overlap with promoter regions), while no hyperDMPs
were found in active H3K27me3 regions (repressive mark)
(Figure 1H). To further support the specific occurrence
of these changes in regulatory regions, we overlapped the
DMPs with ChromHMM annotations of predicted chro-
matin states in MCF-7 (43). We confirmed that the hyper-
DMPs were significantly represented in enhancer and tran-
scribed regions (49.8% and 14.9%, respectively), whereas
they were lowly represented in promoter, CTCF-bound or
repressed regions (1.9%, 0.8% and 0.0%, respectively) (Fig-
ure 1I). These results indicate that the increase in DNAm
in response to E2 deprivation mostly occurs within intronic
regions that contain enhancers.
E2 deprivation globally leads to a decrease of active histone
marks at enhancers
Because the hyperDMPs were found to strongly overlap
with enhancer elements, we sought to evaluate enhancer
activity by measuring changes in H3K27ac levels, which
distinguishes active from primed, poised and inactive en-
hancers (44). For this, we performed ChIP-seq to identify
regions enriched for H3K27ac in CTR and E2D groups
at d14. Altogether, H3K27ac peaks were evenly detected
across promoter, intronic and intergenic regions (Figure
2A). However, the 3053 differentially enriched (DB) regions
(|log2FC| >1, FDR < 0.05) obtained by the comparison of
CTR and E2D groups, were highly enriched and located in
a similar genomic context to DMPs, that is, in intronic and
intergenic regions (42.9% and 41.1%, respectively) that are
mostly corresponding to enhancers (Figure 2A and Supple-
mentary Figure S4A) (43). The large majority of H3K27ac
DB regions showed a lower signal in E2D cells compared
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Figure 2. E2 deprivation globally leads to a loss of H3K27ac at enhancers. (A) Genomic features distribution of ENCODE H3K27ac peaks (n = 33631),
H3K27ac IDR thresholded peaks for CTR and E2D at d14 (n = 31 090 and n = 32 995) as well as for the differentially bound peaks between the two groups
(DB H3K27ac, n = 3053, |log2FC| > 1, FDR < 0.05, n = 2). (B) Global decrease of histone acetylation expressed in log2 normalized reads in DB H3K27ac
regions in CTR and E2D (|log2FC| > 1, FDR < 0.05). DB peaks were separated in decreasing and in increasing acetylation in response to E2 deprivation.
(C) H3K27ac, H3K4me1, H3K27me3 and IgG binding levels after 11 days of CTR and E2D treatments. qPCR data was normalized over input DNA and
presented as the average ± SD of duplicates. Groups were compared using a Student’s t-test within each histone mark. (D) Genome browser snapshot of
H3K27ac normalized ChIP-seq reads in CTR and E2D conditions and ER ChIP-seq reads in E2-treated and untreated MCF-7 (*GSE72249, Swinstead
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treatment, H3K27me3 marks were found to be low at
H3K27ac sites (Figure 2C and Supplementary Figure S4B).
While DMPs and DB regions rarely co-localized (5.0% of
DMPs in a 10 kb window of a DB H3K27ac peak), a signifi-
cant number of genes exhibited both changes within a 1 Mb
distance (Supplementary Figure S4C), suggesting a coordi-
nated but distant regulation of enhancers in cis that depends
on the presence of E2. Furthermore, under E2-stimulated
conditions, 25.9% of DB peaks co-localized with ER bind-
ing events and almost half of the latter (11.2% of total DB
peaks) overlapped with E2-specific ER peaks (38) (Figure
2D, Supplementary Figure S4D). Taken together these re-
sults point to an inactivation of enhancers accompanied by
decreased active H3K27ac mark in response to E2 depriva-
tion, which is consistent with a hypermethylation of DMPs
and potential impact on gene transcription.
Down-regulation of TET2 expression following E2 depriva-
tion and hypermethylation of enhancers
To further characterize the genome-wide impact of ER ac-
tivity on gene regulation and how this is related to epigenetic
status of enhancers, we performed genome-wide transcrip-
tome analysis by NGS-sequencing (RNA-Seq) in CTR and
E2D conditions, in the same samples used for the methy-
lome assays. The analysis revealed that the deprivation of E2
led to 547 differentially expressed genes (DEGs) (|log2FC|
>1 and FDR < 0.05), from which 71.1% were down-
regulated (Figure 3A and B). The down-regulated fraction
was particularly enriched in genes involved in estrogen-
related response (Figure 3C). Canonical ER targets were
found, as expected, among down-regulated genes, such as
GREB1, TFF1 and PGR (Figure 3B). The global down-
regulation in gene expression is in line with the observed
general increase of DNAm and loss of histone acetylation
marks. Nevertheless, the overlap between DEGs and genes
containing DMPs or DB H3K27ac peaks in cis was rela-
tively low compared to the total number of genes (Supple-
mentary Figure S5A). 40 out of the 547 DEGs overlapped
with genes located nearby a DMP and 110 DEGs were as-
sociated with DB H3K27ac peaks (Supplementary Figure
S5A) indicating that the enhancers may not systematically
regulate the expression of the nearest genes.
To identify epigenetic regulators that may be respon-
sible for those DNAm and histone acetylation changes,
we examined ERFs that could be differentially expressed
in response to E2 deprivation. For this, we searched for
gene expression changes among 426 previously identified
ERFs (45) and found that HDAC9, PADI4 and TET2
were significantly deregulated (FDR < 0.05), the latter hav-
ing the highest expression levels (Figure 3D). The expres-
sion of these three ERFs changed significantly and sim-
ilarly to E2D after 4 and 14 days of treatment with ICI
further validating the impact of ER pathway deregula-
tion on their expression (Supplementary Figure S5B). Be-
cause E2 deprivation affected the expression of the 5mC
demethylase TET2 and not the other members of the ten-
eleven translocation (TET) family (TET1 and TET3, Sup-
plementary Figure S5C), we investigated the role of TET2
in DNA methylation changes induced by E2 deprivation.
TET2 knockdown (KD) revealed a decrease in ER targets
(such as GREB1), suggesting a putative role of the TET2
downregulation (observed in E2D) in loss of expression of
ER targets (Supplementary Figure S5D and E). We next
measured 5-hydroxymethylcytosine (5hmC) levels, which
reflect the activity of TET enzymes, in a selection of top
E2-responsive DMPs. Consistent with the array data, 5mC
levels increased after 14 days of E2-deprivation, whereas
5hmC levels were noticeably decreased (Figure 3E). A sim-
ilar trend was also observed when hMeDIP-qPCR experi-
ments were performed (Supplementary Figure S5F). Mea-
suring 5mC and 5hmC levels on the same sites following
TET2 KD further revealed an increase of 5mC levels, sim-
ilar albeit less pronounced as the E2D treatment, and to a
significantly stronger decrease of 5hmC levels (Figure 3F).
Together, the decrease of ER activity and downregulation
of TET2 expression is associated with an increase in 5mC
levels and decrease in 5hmC levels at DMPs of enhancers.
Identifying key ER cofactors in E2-dependent transcriptional
regulation
Our results show that E2 deprivation leads to DNA hyper-
methylation and a decrease in histone acetylation of en-
hancers and that these are partially associated with gene
expression down-regulation in cis and potentially in trans.
As it has been shown that the removal of E2 decreases ER
binding events and time of residence (38), it is expected that
E2 deprivation does not only affect DNA binding of ER but
also of its cofactors. We therefore asked whether the regions
bearing epigenetic changes could be particularly bound by
other TFs. For this we first conducted an enrichment anal-
ysis of transcription factor binding sites in the proximity of
DMPs, DB H3K27ac and DEGs using the ChEA database
(36). Our analysis revealed that in addition to expected en-
richment of ER and ER binding events, binding sites
of other TFs (including ZNF217, TFAP2C and GATA3)
were found enriched in genes that map near DMPs and
DB H3K27ac regions (Figure 4A). These findings support
previously reported functional and physical protein interac-
tions between these TFs and ER (11,46). Interestingly, the
up-regulated fraction of DEGs (n = 166) was enriched for
binding sites of PRC2 members SUZ12 and EZH2, consis-
tent with the fact that when ER is active, it can also ac-
tively repress gene expression (Supplementary Figure S6)
(47). TF binding sites within the down-regulated fraction
of DEGs––that are active when ER is E2-stimulated––were
more enriched in genes containing DMPs. This suggests
that common TFs are involved in the maintenance of these
genes’ epigenetic marks and their expression.
Although informative, the ChEA database is limited by
the number of datasets it contains and provides a broad
picture of TF enrichment based on gene names rather than
specific genomic coordinates. Therefore, to detect putative
DNA-binding TFs in a more unsupervised and focused ap-
proach, we searched for ER and other TF motifs in prox-
imity of E2 deprivation-mediated DMPs and DB H3K27ac
by performing a de novo motif analysis. Our first observa-
tion was the lack of any of the motifs corresponding to the
above-identified TFs, particularly the ER-binding motif,
suggesting that these TFs regulating ER-dependent genes







niversidad del Pais Vasco user on 20 O
ctober 2021
9746 Nucleic Acids Research, 2021, Vol. 49, No. 17
Figure 3. Down-regulation of TET2 expression following E2 deprivation and hypermethylation of enhancers. (A) Distribution of –log10(P-values) of dif-
ferentially expressed genes (DEGs) according to log2 fold-change of expression. Coloured dots represent down- and up-regulated DEGs with an absolute
log2(FC)>1 (blue and red) and a FDR < 0.05 (dashed horizontal). DEGs that were differentially expressed with an absolute log2(FC)<1 are coloured in
dark grey. (B) Top 50 differentially expressed genes (FDR < 0.05) between CTR and E2D at d4 and d14. (C) Gene set enrichment analysis of down-regulated
and up-regulated DEGs (MSigDB, database H, hypergeometric test). (D) Expression of epigenetic remodeling factors HDAC9, PADI4 and TET2 in re-
sponse to E2 deprivation shown as log of counts per million mapped reads (CPM) (FDR < 0.05). (E) 5′-methylcytosine (left) and 5′-hydroxymethylcytosine
(right) levels of top DMPs in CTR and E2D groups at d14 (Student’s t-test, * P < 0.05, ** P < 0.01, *** P < 0.001) and (F) 5′-methylcytosine (left) and
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Figure 4. Key cofactors in E2-mediated chromatin and gene regulation. (A) Enrichment of TF binding over the nearest genes to DMPs (n = 829 genes),
the nearest genes to differentially bound H3K27ac marks (n = 577, ≥2 peaks per gene name) and DEGs (n = 547). Numbers represent the amount of
TFs whose binding was significantly enriched across the different sets of genes (FDR < 0.05). Enrichment of TFs originating from experiments performed
in MCF-7 cells are highlighted in red in the upper right panel (ChEA 2016, Kuleshov et al. 2016). (B) de novo motif analysis performed on 14-day-E2-
deprivation induced DMPs (top 4 hits shown) and DB H3K27ac (top 2 hits shown). The enrichment is the result of the percentage of the motif occurrence
in target sequences over random background genomic sequences. The motif search was expanded over a 500 bp-window for DMPs and a 1 kb-window
for DB H3K27ac peaks. (C) Overlap of DMPs, DB H3K27ac regions and DEGs with a collection of publicly available TF ChIP-seq datasets in MCF-7.
Fold-enrichement was calculated as the fold-change between the percentage of binding overlap within a differential set of hits over the percentage of TF
overlap within the total of 850k CpGs, the H3K27ac regions in CTRs at d14 (IDR peaks) and the total fraction of genes that were expressed in the RNA-
seq. (D) ER binding on a selection of hyperDMPs in CTR and E2D MCF-7 (n = 3). IgG is shown only for CTR. Both anti-ER and anti-IgG ChIPs were
normalized over input. Asterisks indicate significant differences from the IgG (Student’s t-test, P < 0.05). n.s., not significant (Student’s t-test, P > 0.05)
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Figure 5. Partial reversibility of epigenetic and transcription changes induced by sequential deactivation and re-activation of ER. (A) MCF-7 were deprived
of E2 for 4 days, after which they were re-stimulated with E2 for 10 days (ReSt, blue dashed line). (B) Heatmap of hypermethylated DMPs (FDR < 0.05; >
10% ) in response to E2-deprivation for CTR, E2D and ReSt at d14. (C) Distribution of hypermethylated DMPs in CTR, E2D and ReSt at d14 (CTR
versus E2D, n = 950; FDR < 0.05,  > 10%). Box plot: centre lines, median (Q2); box boundaries, 25% and 75% quartiles (Q1 and Q3); top and bottom
whiskers, minimum and maximum (Q0 and Q4). For each pairwise comparison (ReSt-CTR and CTR-E2D), the quartiles are connected with red lines. In
each interquartile range appears in red the mean  between the compared interquartile groups. The mean of each group is shown by a red cross. Asterisks
marks significant differences of ReSt and E2D means compared to CTR (Student’s t-test, * P < 0.01 and *** P < 10–5). (D) DNAm levels of top DMPs
following DMSO treatment (CTR, green), ICI treatment (ICI, orange), and ICI followed by DMSO treatment (ReAc, blue dashed). Results are shown as
the mean of triplicates with 95% of C.I. (Mann–Whitney test at d14, * P < 0.05). (E) Overlap of differentially bound H3K27ac regions between CTR versus
E2D and CTR versus ReSt regions. (F) H3K27ac signal in log2 normalized reads of 207 peaks that were significantly different in both CTR versus ReSt
and CTR versus E2D comparisons. (G) Non reversibility of expression of AP-1 inducer TNIK and AP-1 target gene MMP13 for CTR condition (green
square), E2D (orange diamonds) and ReSt (blue triangles) on day 14. Differential expression analysis was performed by contrasting CTR vs ReSt groups
among E2-deprivation DEGs, FDR < 0.05, |log2FC| > 1. (H) gene expression changes following DMSO treatment for 4 and14 days (CTR, green), ICI
182 780 treatment for 14 days (ICI, orange), and 4 days of ICI 182 780 treatment followed by 10 days of DMSO (ReAc, blue dashed). Relative expression
is expressed as the fold-change of ICI and ReAc treatment over the CTR of the same timepoint. Results are shown as the mean of triplicates with 95% of
C.I. Significance of changes was evaluated with Kruskal–Wallis followed by Dunn’s multiple comparison test where crosses indicate overall significance
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DB H3K27ac regions. Those observations also suggest that
the epigenetically variable enhancers are not necessary di-
rectly bound by ER (Figure 4B). Indeed, a low fraction of
hyperDMPs and H3K27ac regions (7.3% and 26.0%, re-
spectively) overlapped with ER bound regions detected in
MCF-7 cells cultured in presence of E2 (Figure 4C) (38). We
validated this trend by ER ChIP-qPCR showing that ER
binds only one out of the four selected hyperDMPs (Figure
4D).
Interestingly, we found that the motifs matching AP-1
and FOX TFs, known as principal ER cofactors, were en-
riched in proximity to both DMPs and DB H3K27ac re-
gions (Figure 4B and C). Based on these findings and the
knowledge of reported ER cofactors, we overlapped a set
of publicly available TF ChIP-seq datasets in MCF-7 ex-
posed to E2 among other hormones (Supplementary Ta-
ble S4) with DMPs, DB H3K27ac marks and DEGs iden-
tified in this study. We found that FOS and FOSL2 bind-
ing, two AP-1 components, were enriched 9.1-fold and 6.7-
fold, respectively, across DMPs, and across DB H3K27ac
and DEGs (Figure 4C). Although not substantially overlap-
ping, ER, ER cofactor NCOA3 and acetyltranferase p300
that are involved in regulation of transcriptional activity
and AHR were significantly enriched across all differen-
tial datasets (Figure 4C, Supplementary Figure S7). More-
over, the overlap with the ChEA database confirmed that
the promoters mapping closer to DMPs and DB H3K27ac
regions can be bound by ER. Inversely, the majority of DB
H3K27ac peaks and DEGs overlapped with other known
ER cofactors’ binding sites such as FOXA1, GATA3 and
ZNF217 but with a less notable enrichment (Figure 4C,
middle and right panel). This is in line with the preferen-
tial binding of these factors in proximity to active marks or
active genes. Together, these findings emphasize the impor-
tance of ER tethering and suggest that AP-1 may be directly
involved in the maintenance of DNAm. Indeed, downregu-
lation of FOS resulted in loss of DNA methylation at several
of CpGs observed to be hypermethylated in E2D (Figure 4E
and Supplementary Figure S8A).
As cells’ response to our deprivation protocol might show
similarities with the development of resistance in response
to anti-estrogen therapy, we reasoned that ER cofactors
might play similar roles in the chromatin rearrangements
and DNA methylation changes observed in both cases.
Therefore, we overlapped JUN (a component of AP-1 com-
plex) ChIP-seq data analysed in MCF-7 cells and MCF-7
cells that acquired resistance following tamoxifen treatment
(15) with our DB H3K27ac and DMP sites. Interestingly,
we observed a lack of JUN binding at those sites in MCF-7
cells and a gain in binding in ∼25% of lost H3K27ac sites
(E2D versus CTR) and ∼10% of hyperDMPs sites (E2D
versus CTR) which is suggestive of an important regulatory
role of AP-1 complex at those sites (Supplementary Figure
S8B).
Partial reversibility of epigenetic changes following E2 re-
stimulation
Because epigenetic marks can be dynamic, we reasoned that
the changes in DNAm and H3K27ac following E2 depriva-
tion may be reversible when the cells are re-stimulated with
E2. To test this, we deprived MCF-7 cells from E2 for 4
days and added back E2 for another 10 days after which we
analysed DNAm, H3K27ac and transcription profiles (Fig-
ure 5A, Supplementary Figure S9A–C). We first analysed
differences in methylation levels between the re-stimulated
group (ReSt), the CTRs and E2Ds. We looked for changes
across all 850k probes and found no statistically signifi-
cant differences on global levels of DNAm between indi-
vidual probes (Figure 5B). Interestingly, when we narrowed
the analysis to the previously identified E2D-derived hy-
perDMPs, the mean DNAm level was significantly higher
in the ReSt group in comparison to the CTR group (Fig-
ure 5C). It was also notable that hyperDMPs with higher
DNAm levels in CTRs (3rd and 4th quartile) had a higher
difference with ReSt (Figure 5C). The latter was also ob-
served when targeted methylation analyses was performed
at several of the top identified hyperDMPs (Supplementary
Figure S9D). The comparison of E2D to ReSt yielded 44
DMPs, all of which were previously detected among the hy-
perDMPs (CTR vs E2D). To further validate the reversibil-
ity of DNAm changes, we used another approach, where
we inhibited ER activity with its antagonist, ICI, and mea-
sured DNA methylation levels at the top hyperDMPs at day
4 and day 14. To mimic re-stimulation we included also a
group where ER was inhibited with ICI for 4 days and reac-
tivated for another 10 days after the removal of ICI (ReAc)
(Supplementary Figure S9E). Similar to E2-deprivation, we
found that ICI treatment increased DNAm on CpG sites se-
lected among top hyperDMPs (Figure 5D). Although not
significantly different, DNAm levels of ReAc group were
not equal to CTRs at all tested sites, suggesting partial re-
versibility of DNAm levels.
We next evaluated changes in chromatin activity after re-
stimulation with E2 and found 650 H3K27ac regions that
were differentially bound between CTR and ReSt at d14
(Figure 5E). 207 of these regions were also found in the 3053
DB H3K27ac regions that had a lower signal in E2D af-
ter comparison with CTR (Figure 5F). The H3K27ac read
abundance at these 207 regions was significantly lower in
ReSt compared to the CTR group while it was compara-
ble to E2D group, suggesting that H3K27ac levels may have
dropped at d4 and remained stable till d14. The majority of
regions with lower H3K27ac levels in E2D (n = 2846, Fig-
ure 5E) recovered their initial levels.
Finally, we evaluated the reversibility of expression levels
following E2 re-stimulation by RNAseq analyses and found
a recovery of the majority of genes expression following ER
re-stimulation (Supplementary Figure S10A). This recov-
ery included the expression of several known ER targets
(including CREB1, TFF1 and PGR) as well as ERFs (no-
tably HDAC9, PADI4 and TET2) (Supplementary Figure
S10B and C). Similar gene expression recovery was also ob-
served in ReAC cells following ICI treatment (Supplemen-
tary Figure S10D). However, we found that only 6 out of
381 E2D-down-regulated DEGs failed to return to the CTR
level of expression. Interestingly, two of these 6 more stably
altered genes are TNIK and MMP13, respectively an in-
ducer and a target of AP-1 suggesting the possibility of ER
regulating AP-1 activity (Figure 5G). In addition, expres-
sion of TNIK, but not that of MMP13, decreased with ICI
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suggesting that AP-1 pathway could also be deregulated on
the long run in this setting (Figure 5H).
Globally, these results show that epigenetic changes are
largely reversible following E2 re-stimulation. However, a
smaller fraction of the observed changes does not recover,
even when the expression of certain ERFs does, suggesting
the existence of an estrogen-dependent epigenetic memory.
DISCUSSION
In this study, we combined a cell culture protocol adapted
for studying E2 deprivation and restimulation in stricto
sensu with the latest methylation array that allowed a
genome-wide interrogation of methylation states, including
a comprehensive panel of enhancers (48). We found that
prolonged E2 deprivation and re-stimulation result in time
dependent changes in DNAm and histone modifications
(histone acetylation) across diverse genomic regions, many
of which occur within enhancer elements. This is the first
study that comprehensively characterized DNAm and hi-
stone acetylation at enhancers in response to a sequential
inactivation and re-activation of ER signalling. These ob-
servations are consistent with and extend previous studies
showing that ligand-mediated ER activity has an impact on
the epigenome, through a mechanism that likely involves
tethering of ER by other TFs (5,8,21).
While studies have shown that hypermethylation of en-
hancers may be a long-term consequence of reduced ER
activity, our study reveals that gain of methylation at en-
hancers occurs shortly following ER downregulation (in-
duced either by E2 deprivation or ER inhibition) and that
this hypermethylation increases in time. Previous studies
have established that DNA hypermethylation at gene pro-
moters is associated with gene silencing (49). In contrast,
there is scant data on the role of DNAm changes at en-
hancer regions, and the mechanisms that underlie specific
targeting of enhancers for hypermethylation is unclear. It
is known that specific chromatin interactions, involving
DNAm dynamics, are abolished and are replaced by oth-
ers in response to ER activation and inactivation (13,14,43).
Indeed, in some instances DNAm deposition is directed
by TF-mediated DNMT recruitment, whereas in others
DNAm can be the result of the lack of TF occupancy which
exposes these sites to DNMT complexes that have an affin-
ity for unmethylated CpGs (20,50). In 2016, Swinstead et al.
showed using both ChIPseq and single-molecule tracking
that ER binds less frequently and less specifically in the ab-
sence of its ligand (38). Based on the above information, ER
disengagement from chromatin, induced by E2 deprivation,
could make unmethylated CpG sites susceptible to methy-
lation, which is consistent with the observation that methy-
lated DNA represents a default state (51). In an alternative,
although not mutually exclusive scenario, E2 deprivation-
associated hypermethylation may be the result of decreased
demethylating activity at enhancers. Interestingly, we ob-
served both after E2 deprivation and ICI inhibition a de-
crease in expression of DNA demethylase TET2 (Figure
3D, Supplementary Figure S5B and C). Because the activity
of TET2 was associated mainly with gene bodies in a mice
model, the enrichment of hyperDMPs in intronic regions
could also be the result of TET2 down-regulation (52). In-
deed, down-regulation of TET2 in MCF-7 cells resulted in
an increase of methylation and decrease of 5hmC at several
CpGs similar to what was observed in E2 deprivation condi-
tions. The possibility of a double mechanism explaining hy-
permethylation is supported by a recent study showing that
ER not only recruits TET2 on ER-dependent enhancers,
but it also positively regulates TET2 expression in response
to E2 induction, and that TET2 knock-out leads to hyper-
methylation of enhancers (12). This does not exclude an ad-
ditional possible scenario involving a loss of APOBEC3B
(A3B) deaminases at the hyperDMPs. A3B has been pro-
posed to play a role in active DNA demethylation and has
also been shown to co-bind with ER on the genome (53). In-
terestingly, 78 of our detected hyperDMPs overlap with re-
gions previously detected to be co-occupied by A3B and ER
in MCF-7 cells treated with E2 (data not shown) (38). These
findings suggest that following E2 deprivation the binding
of ER and A3B may decrease and their absence at those re-
gions may result in a gain of methylation.
In addition to dynamic levels of DNAm, low density of
CpGs and intermediate levels of DNAm are also character-
istic of enhancers and have been suggested to play a role in
enhancer priming (18,54,55). In line with that, our results
revealed that initial DNAm levels at sites that become hy-
permethylated after E2 deprivation range between 40% and
71% (1st and 3rd quartile) with an average of 55% (Figure
5C). Our ChIP-seq data, showing a decrease of H3K27ac
levels after E2 deprivation, are consistent with a decrease
of enhancer activity. This finding, together with the absence
of overlap with H3K27me3 (Figure 2C and Supplementary
Figure S4B), which is characteristic of repressed and poised
chromatin states, suggests that the identified enhancers may
switch from an active to a primed state in response to E2
deprivation (44,56). ER disengagement from sites carry-
ing DB H3K27ac marks is apparent and correlates with
H3K27ac reduction in almost half of the sites that over-
lap with ER binding (38) (Figure 2D, Supplementary Fig-
ure S6). Just like for DNAm and DNMTs, we hypothesize
that the reduced binding of ER could open the opportunity
to histone deacetylases (HDAC) to act. It is indeed plausi-
ble that the decrease of H3K27ac signal could be related to
the observed increase of HDAC9 expression, although there
is little evidence of a direct relationship between this class
IIa HDAC and H3K27ac deacetylation (57,58). Based on
these findings we propose that the decreased activity of ER
and potentially that of its cofactors renders ER-dependent
enhancers prone to DNA hypermethylation and histone
deacetylation, ultimately tipping the balance from an active
to a primed enhancer configuration (50,59). The decrease
of TET2 and the increase of HDAC9 expression that was
observed in response to both E2 deprivation and ICI inhi-
bition could contribute to the above mechanism, although
further studies are needed to test this hypothesis (Figure 3D,
Supplementary Figure S5B and C).
Because the overlap between changes in gene expression
and epigenetic marks in cis was limited (Supplementary
Figure S5A), we focused on the analysis of the TF net-
work of ER based on the assumption that their binding
to ER-dependent enhancers may also be affected, and con-
sequently impact the epigenetic landscape. Although, our
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supervised and unsupervised approach) failed to identify
ER motifs in proximity to DMPs and DB H3K27ac peaks,
whereas ER binding significantly overlapped with DEGs,
DMPs and DB H3K27ac regions observed after E2 depri-
vation (Figure 4). These results may reflect the frequency
by which ER regulates genomic regions through a tethering
mechanism with other cofactors, rather than through direct
binding (Supplementary Table S5) (5,11). For example, the
CpG site cg10488532 located 250kb upstream from TET2
TSS is hypermethylated in E2D and is dynamically bound
by ER but lacks an ER motif. Interestingly, this CpG is part
of a region that is described to be the putative enhancer E1
of TET2 and is suggested to be regulated by TET2 itself
that may contribute to maintaining active its own enhancer
(5,11,12).
Interestingly, AP-1 and FOX motifs were enriched in
both DMPs and DB H3K27ac regions, and binding of
FOS, an AP-1 component, overlapped with DMPs at sig-
nificantly more sites than other enriched TFs (9.1× and
31% of DMPs, Figure 4C). The absence of ER motif and
the presence of AP-1 motif, combined with a recent study
showing that TET2 occupies ER-related enhancers, as well
as the results from this study and from others showing that
loss of TET2 in MCF-7 leads to hypermethylation at these
enhancers (12,52), support the idea that AP-1 might play a
bridging role between ER and TET2. In this scenario, AP-1
could be involved in the regulation of local DNAm levels as
it was previously shown for FOXA1 (60,61). As FOS silenc-
ing led to a hypomethylation of several E2-responsive CpG
sites (Figure 4E) and these same CpGs were shown to be
hypermethylated when TET2 is lost (Figure 3E and F), it is
possible that AP-1 influence TET2 activity at those regions.
Similarly, the occurrence of AP-1 motif and the enrichment
of acetyltransferase p300 binding sites at DB H3K27ac re-
gions reinforce previously reported AP-1-mediated regu-
lation of histone acetylation by p300 recruitment to en-
hancers (62–64). Our results suggest an important role of
AP-1 at enhancers following cells’ response to changes in
the activity of the ER pathway. This is in line with recent
studies showing that AP-1 (and other TFs) re-organizes en-
hancer landscapes resulting in transcriptional transitions
that promote tumour phenotypic plasticity and resistance
to Tamoxifen (an ER modulator) (65). Although the latter
study shows a high recruitment of JUN (a component of
AP-1 complex) to gained enhancers in MCF-7 cells that ac-
quired resistance, overlapping JUN binding sites with our
DB H3K27ac and DMPs shows a lack of JUN at those
sites in MCF-7 cells and a gain in binding in ∼25% of lost
H3K27ac sites and ∼10% of hyperDMPs sites. Our results
might be reflective of the re-arrangement or recruitment
of AP-1 to enhancer regions that occurs at early stages of
resistance to therapy. Remarkably, AP-1 and FOX motifs
were consistently and highly enriched at all binding sites of
all established ER cofactors investigated (namely TFAP2C,
p300, ZNF217 and AHR) (Supplementary Figure S7). This
is in line with the preferential binding of these factors in
proximity to active marks or active genes. FOXA1 and
GATA3, followed by FOS binding were also significantly
enriched at functional enhancers (defined by an expression–
methylation quantitative trait loci analysis) that distinguish
ER-positive from ER-negative BC subtypes (21). This raises
the possibility that the specific mechanisms are conserved
between cell line models and clinical samples.
Our data also showed that the majority of DNA hy-
permethylation induced by E2 deprivation could be pre-
vented or even reversed when the cells were re-stimulated
with E2 after a period of deprivation or after ICI inhibition
(Figure 5D). Interestingly, although not significantly differ-
ent, DNAm levels of the ER-dependent hyperDMPs were
higher in the re-stimulated group compared to controls.
This trend was more pronounced when DNAm levels were
high (>40%) prior deprivation. When CpG sites that had a
basal low DNAm (<40%) had almost the same level in ReSt
(data not shown). In addition, while the majority of changes
in H3K27ac were recovered following E2 re-stimulation,
the loss of H3K27ac signal in response to E2 deprivation
remained significantly lower in another subset of regions.
These results indicate that DNAm and H3K27ac changes
are precluded from increasing in some regions while they are
reversed in others following ER re-activation, but further
experiments are needed to identify their singular features.
It was previously shown that tamoxifen treatment, another
ER inhibitor, reduces AP-1 binding on ER-dependent sites
and is re-located on new binding sites (66). Although the re-
moval of tamoxifen was not tested, re-distribution of AP-1
binding, that is enriched in our DMPs and DB H3K27ac,
on other genomic locations could explain the lagging recov-
ery of DNAm and histone acetylation on certain enhancers.
It is noteworthy that at the transcriptional level, TNIK
and MMP13 decreased after estrogen deprivation and failed
to recover after a prolonged E2 re-stimulation (Figure 5G
and H). TNIK is required for JNK1 activation, a kinase that
activates the AP-1 complex, whereas MMP13, a metallo-
protease, that is regulated through the same signalling path-
way, is considered as a marker of breast cancer invasiveness
(67,68). This observation combined with the unchanged lev-
els of AP-1 component expression opens the door to the ex-
ploration of nongenomic signalling that is not addressed in
this study. Although we could not rule out the possibility
that duration of deprivation followed by re-stimulation was
not sufficiently long enough to observe a full reversal of epi-
genetic changes, a selective retention of DNA methylation
changes, indicative of epigenetic memory (69), is consistent
with the notion that the disruption of ER and its impact on
ER cofactors’ pathways including AP-1 signalling may be
involved in endocrine resistance (66,70,71).
Based on our results, we propose a model in which ligand-
activated ER and its cofactors orchestrate an intricate in-
teraction in cis and trans between promoters and a panel
of epigenetically dynamic enhancers (Supplementary Fig-
ure S11). Under continuous E2 exposure, AP-1 contributes
to the maintenance of balance between TET2 and DNMT
proteins in order to keep DNAm at intermediate levels in
intronic enhancers while, in collaboration with p300 and
FOXA1 proteins, AP-1 preserves histone acetylation in dis-
tal enhancers and thereby maintains gene expression. In
this scenario, the lagging recovery of DNAm and histone
acetylation levels at certain enhancers could be the result
of the partial redistribution of AP-1 binding sites away
from ER-responsive regions, as it was previously observed
in tamoxifen-treated cells (66,70). In parallel to this mecha-
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could contribute to the enhancers’ shift from an active to a
primed state.
In summary, this study provides mechanistic insight into
the events by which estrogen receptor and its cofactors me-
diate changes in DNA methylation and chromatin states
at enhancers in response to estrogen deprivation and re-
stimulation. The selective reversibility and persistence of
DNA methylation and histone acetylation changes ob-
served after estrogen deprivation/re-stimulation, suggest a
potential mechanism underlying the ‘roots’ of endocrine
resistance that commonly develops in response to anti-
estrogen therapy. This insight may open new research av-
enues to investigate epigenetic modifications at enhancers
and how estrogen receptor binding may participate in ER
positive breast cancer drug/treatment resistance.
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